Bruce F

Bruce F.

location_on

Bethesda, MD & Sarasota, FL, États-Unis

Niveau d'investissement

€9,000 - €250,000

calendar_today
person Autre
public États-Unis

Professional background

Initially a published scientist (100+publications, NIH grants/study section member) Ph.D. in Microbiology/Immunology. Attorney in FDA regulatory areas - device, drugs, biologics, biotech,...) for 28 years (retired) with leading law firms, Venture Partner, TVM (retired) and now high net worth investor and participant in start-up biomedical companies as Board member, Management Team and fund raiser. Using the experience of counseling large and mid-size and early stage pharma (traditional, biotech, generic,...), as Board member with several drug, vaccine and medical technologies companies in which I have invested

Domaines d'expertise

As an Immunologist/microbiologist publishing over 100 publication, I have a good grasp of scientific nuances impacting on biomedical companies, and have used this scientific knowledge in interacting with FDA, Health Canada, EMA, PMDA (Japan) etc. I was on both an NIH study section as a reviewer, then on a NHLI SBIR/STTR review group until 2020. I have spent almost 30 years as a private attorney in the FDA, USDA, EPA,...areas counseling companies developing products - medical/diagnostic devices, traditional/biotech new drugs and generics, biologics, and companies developing biotech products.
As an attorney, I performed FDA due diligence for venture capital groups, and was a consultant/venture Partner to TVM (Muinch/Boston). Retiring from FDA practice I have helped start several biomedical companies, invested in several start-ups, on the Board of several drug, vaccine and medical technologies companies, and been an investor in several early biomedical startups ($10,000-$300,000).

Entreprises

EP
Ethicann Pharmaceuticals Inc.
Founder

Ethicann Pharmaceuticals (Sarasota/Bethesda MD/Toronto, CN) based specialty pharma company that reformulates approved drugs with safety issues into safer, metered sublingual doses and achieves rapid approvals using abbreviated new drug approval strategies (2025 > Canada, UK, Germany, EU & FDA). Have had successful meetings with FDA and Health Canada to confirm approval strategies. First product to treat MS spasticity only requiring human bioequivalence for new drug approval Canada, UK, Germany & EU; US 505b2 NDA. Using proprietary oral disintegrating tablet (ODT) delivery (Catalent) and ultra-high purity APIs to avoid impurities. www.ethicann-pharma.com . Have just closed $1.5M convertible note, executed license for proprietary Zydis oral disintegrating tablets (ODT) with Catalent, UK. Active fund rasier for Ethicann, will be at JP Morgan Healthcare Conference, talking with investment bankers, VCs and ultra-high net worth investors.

Intérêts

Secteurs

Médecine et Pharma

Médecine et Pharma

Produits et Inventions

Produits et Inventions

Technologie

Technologie

Finance

Finance

Stades

Pré-démarrage/R&D Produit fini Réalisation des ventes Seuil de rentabilité Rentable Autre

Secteurs

Aucun secteur saisi pour le moment.

Régions

Midwest (Centre-Ouest) Sud-Est Ouest Sud-Ouest Nord-Est

Pays

États-Unis Allemagne Royaume-Uni Australie

Rejoignez notre réseau d'entrepreneurs et d'investisseurs en pleine croissance

AIN aide les investisseurs et les entrepreneurs à établir des relations durables et rentables en vue de créer de meilleures entreprises et un avenir plus prometteur.

Loading…
Loading the web debug toolbar…
Attempt #